The first year of hair loss treatment: what the product information actually says
Twelve months of treatment produces a change smaller than the difference between two bathroom mirror photos. That is the whole problem with judging it by eye.
Combining hair loss treatments: what the licensed evidence actually covers
The pairing marketed everywhere as the gold standard is described by the UK product information in four words: no data are available.
Vardenafil and avanafil: how they differ from sildenafil and tadalafil
Four medicines, one mechanism, and a surprisingly small number of real differences. The ones that exist are onset, duration and what you had for dinner.
Alprostadil cream and pellets: the needle-free routes explained
Less effective than injecting, considerably less daunting. The trade-off is the whole story, and the partner warnings are the part most pages leave out.
Alprostadil injections: how they are started, dosed and monitored
The most effective medical treatment for erectile dysfunction, and the one with the most rules attached. Both of those facts matter.
Weight loss medicines before surgery: UK guidance says continue
UK national guidance and US national guidance say opposite things, and some UK hospitals follow the US version anyway. The one instruction that holds everywhere is to tell the team.
Missed doses: the catch-up windows, product by product
Every product has a different rule, the oral tablet has no rule at all in the sense people expect, and the one thing none of them permit is taking two.
Injection technique and sites: what the UK recommendations actually say
Most of what goes wrong is not the needle going in. It is coming out too early, going back into the same square inch every week, or a used pen with nowhere to go.
Alopecia areata: an autoimmune condition, not pattern baldness
Round, smooth patches that appear over weeks are a different condition from a receding hairline, with a different cause, a different treatment and a far less predictable course.
Topical finasteride: what is actually available in the UK, and what gets absorbed
Marketed as the version without systemic effects. The phase III data show serum DHT falling by about a third, which is not nothing, and the pharmacovigilance data agree.